Impact of SGLT2 inhibitors on heart failure risk and kidney function in type 2 diabetic mellitus patients: A literature review
International Journal of Applied Mathematics, Sciences, and Technology for National Defense · 27.07.2026 · 4 (2) · 95-106
DOI: 10.58524/app.sci.def.v4i2.1134 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Applied Mathematics, Sciences, and Technology for National Defense, online erschienen am 27.07.2026. Verfasst von Chelsy Vanya Br. Meliala und 5 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY-SA 4.0).
Themen: Herzinsuffizienz
Abstract (Originalsprache)
Background
Type 2 diabetes mellitus is known to be closely associated with an increased risk of heart failure and chronic kidney disease, both of which are major causes of illness and death in diabetic patients. In recent years, sodium-glucose cotransporter-2 inhibitors (SGLT2i), which were initially developed as blood glucose-lowering drugs, have been shown to provide additional benefits beyond glycemic control, particularly in protecting the heart and kidneys.
Aims
This literature review aims to comprehensively evaluate the impact of SGLT2 inhibitor use on the risk of heart failure and renal function outcomes in patients with type 2 diabetes mellitus (T2DM).
Method
A literature search was conducted through the PubMed, Scopus, and ScienceDirect databases for publications from 2015 to 2025, including randomized controlled trials (RCTs), meta-analyses, and systematic reviews using the keywords "SGLT2 inhibitors," "heart failure," "renal outcomes," and "type 2 diabetes." Results: from various large clinical trials and meta-analyses show that SGLT2 inhibitors consistently reduce the risk of hospitalization due to heart failure and cardiovascular death, with a hazard ratio generally below 0.80. In addition, this therapy also slows the decline in glomerular filtration rate (eGFR), thereby reducing deaths due to renal causes.
Conclusion
SGLT-2i has been shown to provide strong cardio-renal protection in patients with T2DM, especially in individuals at high risk of heart failure or chronic kidney disease, in accordance with current clinical guidelines.
Zitieren
APA
Meliala, C. V. B., Tuba, S., Priyono, A., Sulaiman, S. A. S., Sumaryono, B., & Sari, E. P. (2026). Impact of SGLT2 inhibitors on heart failure risk and kidney function in type 2 diabetic mellitus patients: A literature review. International Journal of Applied Mathematics, Sciences, and Technology for National Defense, 4(2), 95-106. https://doi.org/10.58524/app.sci.def.v4i2.1134
Vancouver
Meliala CVB, Tuba S, Priyono A, Sulaiman SAS, Sumaryono B, Sari EP. Impact of SGLT2 inhibitors on heart failure risk and kidney function in type 2 diabetic mellitus patients: A literature review. International Journal of Applied Mathematics, Sciences, and Technology for National Defense. 2026;4(2):95-106. doi:10.58524/app.sci.def.v4i2.1134
BibTeX
@article{Meliala2026,
author = {Meliala, Chelsy Vanya Br. and Tuba, Syahrul and Priyono, Adi and Sulaiman, Syed Azhar Syed and Sumaryono, Budi and Sari, Endah Permata},
title = {Impact of SGLT2 inhibitors on heart failure risk and kidney function in type 2 diabetic mellitus patients: A literature review},
journal = {International Journal of Applied Mathematics, Sciences, and Technology for National Defense},
year = {2026},
volume = {4},
number = {2},
pages = {95--106},
doi = {10.58524/app.sci.def.v4i2.1134}
}
EUVIMED